Navigation Links
Generex Subsidiary Antigen Express Announces Press Conference at American Association for Cancer Research Related to the Immunological Response of its AE37 Vaccine to Prevent Recurrence of Breast Cancer
Date:4/3/2012

WORCESTER, Mass. and TORONTO, April 3, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) announced today that the American Association for Cancer Research (AACR) chose to spotlight a presentation on data from the ongoing clinical trial of AE37, an immunotherapeutic vaccine to prevent relapse in patients who have had breast cancer being developed by Antigen Express, in a press conference.  The annual AACR meeting is one of the largest national cancer conferences in the US, highlighting the most significant advances in all areas of cancer research.  It is being held this year from March 31 to April 4 at McCormick Place in Chicago, Il.

The specific presentation highlighted by the AACR is entitled: "Immune response assessment in a phase II trial of AE37 HER2 peptide vaccine" by Dr. Diane Hale et al.  The abstract will be available for viewing Tuesday April 3rd from 8 AM to 12 PM.  The study examined patients from the controlled, randomized trial of AE37 for immunological response to the vaccine.  AE37 consists of a fragment of the HER2 protein modified by proprietary means to increase potency in generating a specific immune response to HER2 expressing cancer cells.  The key findings from the study are that patients receiving AE37 indeed developed a specific immune response as indicated by an increase in circulating T cells in their blood specific for the HER2 fragment as well as a positive skin test (delayed type hypersensitivity).  In addition, patients receiving AE37 demonstrated a reduction in T regulatory cells, which are know to be able to hamper an immune response.

The AACR press conference was held Monday April 2nd.  Dr. Hale gave a brief oral presentation of the study followed by a question and answer period.

"The finding that AE37 generates a specific immune response is consistent with the activity we've observed to date, suggesting that patients receivi
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Generex Announces Patent Award for its Core Vaccine Technologies in Japan
2. Generex Secures Commitments for $3.6M Capital Raise
3. Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccines Clinical & Regulatory Strategy
4. Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today
5. Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai
6. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
7. Generex Makes Podium Presentation of Clinical Data on Generex Oral-lyn™ at European Association for the Study of Diabetes Annual Meeting
8. Generex Provides Update on Spinout of Antigen Express
9. Generex Augments Cash Position With Sales of Non-Essential Assets
10. Amarantus BioSciences and Generex Biotechnology Collaborate on Cell Therapy for Late Stage Diabetes
11. Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 DTS Language Services, Inc . ... Portal for Life Science organizations who need document translations. ... matter of their documents in advance with a selection of ... of translations, often a critical factor in clinical and scientific ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: ... 1360 Almshouse Road, Warrington, Pa. , Details: The ... to finding a cure for hepatitis B and improving the ... annual Crystal Ball on Friday, April 11 at Warrington Country ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 EquitiesIQ, a ... Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company ... the wound care market. , Free report download: ... with a seasoned management team and Board, which launched ...
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: ... and commercializing innovative therapies addressing major unmet medical ... received the Notice of Allowance from the United ... self-delivering RNAi compounds (sd-rxRNA®), for the treatment of ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... LUMBY, BC, Sept. 1 /PRNewswire-FirstCall/ - avVaa World Health ... company, manufacturer and distributor of nationally branded therapeutic, natural ... successfully completed its first week of DRTV 120/60 second ... President and COO of avVaa World Health Care Products ...
... Delaware, September 1 According to a new,market research ... http://www.marketsandmarkets.com ), the,global autoimmune treatment market is expected ... CAGR of 12.7% from 2009 to 2014. The North,American ... the total revenues. , Browse ...
... ... + Phillips, Media Investment Bankers, has announced that James R. Brennan, ... IncumediX and COO/CSO at MediServe Information Systems, Jim currently runs a ... acquisitions, technology license and partnership deals, notably the sale of VanSlyck ...
Cached Biology Technology:avVaa World Health Care Products, Inc. Announces the completion of its first week of DRTV 120/60 second test commercials for Neuroskin(R) Psoriasis Relief 2MarketsandMarkets: Global Autoimmune Treatment Market Worth US$68.81 Billion by 2014 2MarketsandMarkets: Global Autoimmune Treatment Market Worth US$68.81 Billion by 2014 3MarketsandMarkets: Global Autoimmune Treatment Market Worth US$68.81 Billion by 2014 4DeSilva + Phillips, Mediabankers, names Jim Brennan to Head Healthcare IT M&A Practice 2DeSilva + Phillips, Mediabankers, names Jim Brennan to Head Healthcare IT M&A Practice 3
(Date:4/22/2014)... of breeding bird surveys sent in by citizen scientists ... years, wildlife researchers report that most of the 40 ... higher elevation in response to climate change, but did ... previous studies of potential climate change impacts on wildlife ... have likely underestimated the effects of environmental warming, say ...
(Date:4/22/2014)... is available in French . ... month, sequencing of the complete genome and subsequent phylogenetic ... a clade (variant) that is distinct from strains previously ... Gabon. Epidemiological investigations also linked the laboratory confirmed cases ... outbreak. , Ebola virus is a lethal, highly contagious ...
(Date:4/22/2014)... demonstrate how communities can protect themselves from worsening ... in New England and the Midwest providing practical ... "Our goal is to help communities begin the ... Stack, of Syntectic International, Portland, OR. "It,s important ... move beyond feeling paralyzed from the lack of ...
Breaking Biology News(10 mins):Wildlife response to climate change is likely underestimated, experts warn 2Inserm and the Institut Pasteur identify a new variant of Ebola virus in Guinea 2Minnesota projects offer hope and practical help to communities facing more extreme storms 2
... of the journal Cell Metabolism, published by Cell Press, ... glands of mammals meet the incredible metabolic demands of ... undoubtedly affect breast cancer, the findings may have therapeutic ... one of three “isoforms?of the gene known as Akt ...
... of biologists at New York University's Center for Comparative Functional ... The gene plays a part in ensuring that chromosomes are ... nuclear envelope function. The findings appear in the journal Current ... is using functional genomic tools to study the nematode worm ...
... war against flu, researchers at the University of Wisconsin-Madison ... confers broad protection against influenza viruses, including deadly avian ... (Oct. 4, 2006) in the Journal of Virology, describes ... molecule -- that effectively blocks the influenza virus from ...
Cached Biology News:How mammals fuel milk production may have implications for cancer 2How mammals fuel milk production may have implications for cancer 3NYU biologists identify gene that coordinates two cellular processes 2New drug blocks influenza, including bird flu virus 2New drug blocks influenza, including bird flu virus 3
Comp Dim: chamber diam. depth 20 2.8 mm chamber maximum volume 720 μL...
...
... A direct, simple approach ... the well surface of an ... anhydride maintains its integrity and ... under dry, room temperature conditions ...
... reagent; Ideal for clarifying many items ... nucleic acids, & proteoglycans; Contains no ... downstream processing; Utilizes a reagent that ... as a suspension in saline; Simple ...
Biology Products: